Can a rheumatoid arthritis drug tame CAR-T's worst side effects?
NCT ID NCT04359784
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This phase 2 trial tested whether anakinra, a drug normally used for rheumatoid arthritis, can prevent two serious side effects of CAR-T cell therapy: cytokine release syndrome (CRS) and nerve damage. The study enrolled 27 adults with B-cell non-Hodgkin lymphoma who were receiving CAR-T treatment. Researchers gave anakinra alongside CAR-T therapy and monitored for CRS and neurotoxicity.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Anakinra (a drug used for rheumatoid arthritis)
What this could lead to
If it works, anakinra could help make CAR-T cell therapy safer by reducing severe side effects like cytokine release syndrome and nerve damage.
What could go wrong
This is a small, early-phase trial with only 27 participants, so results may not apply broadly. Anakinra may not prevent these side effects and could have its own risks.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for B-CELL NON-HODGKIN LYMPHOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Fred Hutch/University of Washington Cancer Consortium
Seattle, Washington, 98109, United States